A revolution in breast cancer diagnostics and the design of personalized treatment



The way to accurate diagnosis

In the fight against breast cancer, accurate diagnosis is critical to saving lives. Our innovative research use only (RUO) diagnostic test combines advanced molecular technologies to revolutionize breast cancer diagnostics. Backed by state-of-the-art patented technology, unparalleled accuracy, and personalized results, we are changing the game.

Another milestone in the diagnostics of breast cancer 

Welcome to a new era in the accurate diagnosis and personalized treatment. 

Our advanced Multiplex8+ RUO diagnostic test uses a breakthrough RNA quantification technology to provide accurate and reliable results, giving healthcare providers the confidence they need. 

MultiplexDX conducted a massive retrospective validation on 1082 breast cancer samples from prestigious European biobanks demonstrating analytical validity, better stratification of 30% of patients, and prediction of a broad spectrum of therapies.

Key Features:

  • Use of an existing biopsy or surgical resection, no new biopsy needed
  • The most comprehensive analysis of 20,000+ protein-coding and non-coding tumor-specific biomarkers as well as 200+ genes/gene signatures that predict treatment response
  • Cross-validation of key markers with two quantitative methods eliminating the risk of errors
  • Rapid results within three weeks
  • Personalized results includes information on the molecular profile of the tumor and gene/gene signatures relevant to personalized treatment and patient prognosis
  • Provides the oncologist with critical information for more accurate diagnosis and treatment selection
  • Is relevant for all stages of the cancer journey

How does it work? 

Our Multiplex8+ RUO diagnostic test combines cutting-edge imaging techniques, laser capture microdissection, and next-generation sequencing with sophisticated algorithms to analyze breast tissue at the microscopic and molecular levels. This comprehensive approach enables accurate determination of diagnosis, the detection of tumor heterogeneity, and the design of personalized treatment.

Process:

  1. Oncologist submits a test request with patient consent
  2. Multiplex8+ uses a pre-existing FFPE biopsy or surgical resection, no new biopsy needed
  3. Microscopic analysis of tissue (basic histological staining and fluorescence in-situ hybridization) and quantification of biomarkers using machine learning/artificial intelligence to identify regions of interest
  4. Laser capture microdissection to separate regions of interest for spacially-resolved sequencing
  5. Next-generation sequencing and advanced biomarker quantification using using proprietary bioinformatic pipeline
  6. A tailored report based on patients' unique clinical parameters that provides treatment information based on clinical and scientific evidence, mechanisms of action and tumour biolology
  7. Consultation with the oncologist

Strengthening personalized treatment

Each patient is unique and so should be the way they are treated. 

Our Multiplex8+ RUO diagnostic test goes beyond universal approaches. It provides personalized information that allows physicians and healthcare providers to tailor treatment plans to the needs of each individual.

Advantages:

  • Detection of tumor heterogeneity
  • Tailored treatment information
  • Superior clinical accuracy 
  • Suitable for all stages of the cancer journey
  • Can inform second opinions

Pushing the boundaries of expertise

Our team of top researchers and medical professionals led by Dr. Pavol Čekan is committed to advancing breast cancer diagnostics. We adhere to the highest standards of quality and accuracy to ensure the best possible care. Our research procedures are patented.

Why choose MultiplexDX

  • Cutting-edge patented technology
  • ISO 9001 certified labs
  • Multidisciplinary team with extensive expertise in pathology, clinical science, bioinformatics, genomics and molecular biology
  • Active clinical studies programs in collaboration with leading clinical institutes
  • Backed by world class science published in high impact journals

Take the next step

Breast cancer patients who are interested in more information about Multiplex8+ testing should discuss options with their oncologist. MultiplexDX is committed to helping oncologists provide the best possible care for breast cancer patients.